PIFELTRO Film-coated tablet (2023)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Pifeltro 100 mg film-coated tablets.
Qualitative and quantitative composition
Each film-coated tablet contains 100 mg of doravirine. <u>Excipient with known effect:</u> Each film-coated tablet contains 222 mg lactose (as monohydrate). For the full list of excipients, see section ...
Pharmaceutical form
Film-coated tablet (tablet). White, oval-shaped, tablet of dimensions 19.00 mm x 9.50 mm, debossed with the corporate logo and 700 on one side and plain on the other side.
Therapeutic indications
Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with human immunodeficiency ...
Posology and method of administration
Therapy should be initiated by a physician experienced in the management of HIV infection. Posology The recommended dose is one 100 mg tablet taken orally once daily with or without food. Dose adjustment ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers is contraindicated ...
Special warnings and precautions for use
NNRTI substitutions and use of doravirine Doravirine has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy. NNRTI-associated mutations detected at screening ...
Interaction with other medicinal products and other forms of interaction
Effects of other medicinal products on doravirine Doravirine is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A are expected to affect the clearance of doravirine (see ...
Fertility, pregnancy and lactation
Pregnancy There are no or limited amount of data from the use of doravirine in pregnant women. <u>Antiretroviral pregnancy registry:</u> To monitor maternal-foetal outcomes in patients exposed to antiretroviral ...
Effects on ability to drive and use machines
Pifeltro has a minor influence on the ability to drive and use machines. Patients should be informed that fatigue, dizziness, and somnolence have been reported during treatment with doravirine (see section ...
Undesirable effects
Summary of the safety profile In phase 3 clinical trials with doravirine plus 2 NRTIs, the most frequently reported adverse reactions were nausea (4%) and headache (3%). Tabulated summary of adverse reactions ...
Overdose
There is no information on potential acute symptoms and signs of overdose with doravirine.
Pharmacodynamic properties
<b>Pharmacotherapeutic group:</b> Antivirals for systemic use <b>ATC code:</b> J05AG06 Mechanism of action Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV-1 and inhibits ...
Pharmacokinetic properties
Absorption The pharmacokinetics of doravirine were studied in healthy subjects and HIV-1 infected subjects. Doravirine pharmacokinetics are similar in healthy subjects and HIV-1-infected subjects. Steady ...
Preclinical safety data
Reproductive toxicity Reproduction studies with orally administered doravirine have been performed in rats and rabbits at exposures approximately 9 times (rats) and 8 times (rabbits) the exposure in humans ...
List of excipients
<u>Tablet core:</u> Croscarmellose sodium (E468) Hypromellose acetate succinate Lactose monohydrate Magnesium stearate (E470b) Microcrystalline cellulose (E460) Silica, colloidal anhydrous (E551) <u>Film-coating: ...
Incompatibilities
Not applicable.
Shelf life
30 months. After first opening of the bottle use within 35 days.
Special precautions for storage
Store in the original bottle and keep the bottle tightly closed in order to protect from moisture. Do not remove the desiccant. This medicinal product does not require any special temperature storage conditions. ...
Nature and contents of container
Each carton contains a high density polyethylene (HDPE) bottle with a polypropylene child-resistant closure with silica gel desiccant. <u>The following pack sizes are available:</u> 1 bottle with 30 film-coated ...
Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
Marketing authorization number(s)
EU/1/18/1332/001 EU/1/18/1332/002
Date of first authorization / renewal of the authorization
Date of first authorisation: 22 November 2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: